Drug Database
SH

SH-U-454

✓ Approved

Bayer AG · Small Molecule · Small Molecule

What is SH-U-454?

SH-U-454 is a small molecule developed by Bayer AG. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

CompanyBayer AG
Drug ClassSmall Molecule, Imaging Agents
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Bayer AG

Therapeutic Indications

SH-U-454 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Cardiac disordersArteriosclerosis coronary artery✓ Approved

Related Research Articles

PubMedArchivos espanoles de urologia2026-10-15

Predictive Value of Inflammatory Markers Combined With Urinary Biomarkers for 28-Day Outcomes in Patients With Urosepsis: A Retrospective Study.

Mao Jun J, Chen Chao C, He Jiao J, Zhou Lindong L et al.

Urosepsis is a life-threatening complication of urinary tract infection (UTI) associated with high mortality. Early identification of patients at high risk of poor outcomes remains challenging due to the limited predictive value of single biomarker. We retrospectively analysed 148 patients with urosepsis admitted to Tianjin Medical University General Hospital between October 2022 and October 2025. Baseline clinical characteristics, laboratory markers (high-sensitivity C-reactive protein [hsCRP], procalcitonin [PCT], serum creatinine [Scr], β2-microglobulin [β2-MG], and urinary orosomucoid-to-creatinine ratio [u-ORM/u-CREAT]) and 28-day outcomes were collected. Patients were classified into favourable prognosis (n = 102) and poor prognosis (n = 46) groups. Between-group differences were analysed using appropriate parametric, nonparametric, or categorical tests. Prognostic factors were evaluated by univariate and multivariable logistic regression, and predictive performance was assessed by receiver operating characteristic (ROC) curve analysis. The levels of hsCRP, PCT, Scr, β2-MG, and u-ORM/u-CREAT were significantly higher in the poor prognosis group than in the favourable prognosis group (all p < 0.001). Multivariable analysis identified hsCRP >85.3 mg/L, PCT >5.7 ng/mL, Scr >132 μmol/L, and u-ORM/u-CREAT >18.5 mg/mmol as independent predictors of poor prognosis (all p < 0.05). A combined model of hsCRP, PCT, Scr, and u-ORM/u-CREAT achieved the highest predictive performance, with an area under the ROC curve of 0.923, a sensitivity of 86.9% and a specificity of 84.3%, and outperformed individual marker (all p < 0.05). Combined assessment of hsCRP, PCT, Scr, and u-ORM/u-CREAT showed high predictive value for poor 28-day clinical outcomes in urosepsis and may support early risk stratification.

PMID 42876126
Read full article →
PubMedJournal of Alzheimer's disease reports2026-10-15

Assessment of an automated telesurveillance system on serious falls prevention in an elderly suffering from dementia specialized care unit: The URCC GET-BETTER study (geriatric environmental telecare - behavioral engineering technology to enhance rehabilitation).

Sawadogo Abdoul Razak AR, Gayot Caroline C, Ndiaye Amadou Maguette Djiogomaye AMD, Nys Jean François JF et al.

"Unités de réadaptation cognitivo-comportementale (URCC)" are specialized units for patients with Alzheimer's disease or related dementias presenting behavioral disorders. Falls are frequent in these settings, with dementia increasing fall risk six-fold. Detection remains difficult, especially at night when staff presence is reduced. Automated telesurveillance systems (ATS) may help improve fall detection and prevention. To assess the impact of ATS on the prevention of serious nocturnal falls in URCC. We conducted a prospective, multicenter, randomized clinical trial including 344 patients in the URCC units of Brive and Limoges. Patients in the intervention group were monitored with ATS, while controls stayed in rooms without ATS. Patients had a mean age of 83.6 years (SD = 6.1), with 58% women. The cumulative incidence of serious nocturnal falls was 0.01 (SD = 0.02) per patient per stay, with no difference between groups (U = 13,739; p = 0.262). For non-serious nocturnal falls, incidence was 0.03 (SD = 0.07) in the intervention group versus 0.01 (SD = 0.04) in control group (U = 15,391; p = 0.054). Total nocturnal falls were similar (0.03 versus 0.02; U = 14,684; p = 0.529). ATS allowed detection of more non-serious nocturnal falls, potentially enabling tailored prevention strategies to reduce future falls. Further studies are needed to evaluate the effectiveness of these interventions. ClinicalTrials.gov NCT01561872 (registered 13/02/2015).

PMID 42876868
Read full article →
PubMedThe Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians2026-10-15

Evaluation of Chromium Picolinate Supplementation and Insulin Requirements in Critically Ill Adults With Type 2 Diabetes Mellitus.

Tomika Alvin A, Finnell Corey C, Yann Reesie R, Bui Phuoc Tyler PT

Chromium picolinate has been studied as an adjunct to improve glycemic indices in ambulatory type 2 diabetes mellitus, but its role in critically ill patients is unknown. To evaluate whether chromium picolinate supplementation was associated with reduced insulin requirements without worsening glycemic control in critically ill adults with type 2 diabetes mellitus. We conducted a single-center retrospective pre-post cohort study of adult intensive care unit patients with type 2 diabetes mellitus or hemoglobin A1c ≥6.5% who received insulin and at least 4 consecutive chromium picolinate doses between July 2022 and January 2023. Patients served as their own controls during 24-hour pre- and post-chromium periods. The primary outcome was change in total daily insulin dose. Secondary outcomes included proportion of measured glucose values within 140 to 180 mg/dL, acute kidney injury, hypoglycemia, and exploratory Sequential Organ Failure Assessment-2 change. Among 91 screened patients, 45 met the inclusion criteria. Median total daily insulin dose decreased from 76.3 U/d (interquartile range [IQR], 40.1-96.9) before chromium to 40.0 U/d (IQR, 20.5-65.6) after chromium; the Hodges-Lehmann paired difference was -23.0 U/d (95% CI, -33.25 to -14.25; P < .0001). Proportion of measured glucose values within target did not differ significantly. No post-intervention hypoglycemia was observed, and 2 patients met the study-defined acute kidney injury criterion. Interpretation is limited by the retrospective design and absence of a concurrent control group. Chromium picolinate supplementation was associated with lower insulin requirements without worsening glycemic control. These hypothesis-generating findings require confirmation in prospective controlled studies.

PMID 42876873
Read full article →
PubMedJournal of Alzheimer's disease reports2026-10-15

Smaller pineal volume in Alzheimer's disease than in dementia with Lewy bodies.

Matsuoka Teruyuki T, Kobayashi Ryota R, Imai Ayu A, Sakamoto Kazutaka K et al.

Pineal gland volume reduction in Alzheimer's disease (AD) has been reported. Recent findings also indicate an association between pineal volume reduction and dementia with Lewy bodies (DLB). This study aimed to compare pineal volume between two major neurodegenerative disorders: AD and DLB. This cross-sectional analysis included patients with AD or DLB who underwent brain magnetic resonance imaging (MRI) and Mini-Mental State Examination (MMSE). AD was diagnosed based on the National Institute on Aging-Alzheimer's Association criteria and confirmed by positive amyloid positron emission tomography. DLB was diagnosed per McKeith et al.'s clinical criteria and confirmed by dopamine transporter single-photon emission computed tomography or 123I-metaiodobenzylguanidine myocardial scintigraphy. Pineal parenchymal volume (PPV) was manually measured using MRI data. The Mann-Whitney U test was used for group comparisons, and analysis of covariance (ANCOVA) was performed with logarithmic transformation since PPV was not normally distributed. Covariates included total intracranial volume, age, sex, MMSE score, use of antidementia drugs, use of psychotropic medications, and MRI magnetic field strength. Seventy-five patients (AD, 41; DLB, 34; 35 women) were analyzed. PPV was significantly smaller in the AD group than in the DLB group (74.7 ± 18.8 versus 96.0 ± 31.6 mm3, U = 1024, p < 0.001). ANCOVA confirmed a significant diagnostic effect (F = 11.9, p < 0.001). Pineal volume was smaller in AD than in DLB; this difference may reflect the neuropathological characteristics specific to AD.

PMID 42876878
Read full article →
PubMedAdvanced materials (Deerfield Beach, Fla.)2026-10-15

Dual Twisted Interfaces Enable Tunable Second Harmonic Generation in Chemical Vapor Deposition Grown Trilayer MoS2.

Guo Mengxuan M, Xuan Luyun L, Zhang Mingwen M, Zhang Han H et al.

Twisted bilayer transition metal dichalcogenides, governed by a single twisted interface, offer a versatile platform for manipulating interlayer coupling and emergent optical behavior. However, despite extensive studies on single twisted interface systems, how multi-interface twisted stacking influences nonlinear optical behavior remains unclear. Here, we address this gap by systematically investigating the nonlinear optical performance of chemical vapor deposition (CVD) grown twisted trilayer MoS2 (TT-MoS2) with multi-interface twisted stacking. We fabricate all nine distinct trilayer MoS2 configurations by CVD. Raman and photoluminescence show that twisted interfaces modulate interlayer coupling, giving rise to stacking-dependent phonon and excitonic responses. Atomic-resolution scanning, transmission electron microscopy, and selected area electron diffraction confirm dual twisted interfaces and a supermoiré lattice. Guided by these structural insights, we examine the second harmonic generation (SHG) response across all nine trilayer configurations. Extending the coherent SH field superposition model to a trilayer system with two independent twisted interfaces, we develop a framework that describes how the dual interfaces govern the SHG intensity and polarization orientation across stacking configurations. Our findings establish TT-MoS2 as a versatile nonlinear platform and open new avenues for understanding and exploiting multi-interface twisted coupling to engineer nonlinear optical responses in van der Waals materials.

PMID 42876215
Read full article →
PubMedJournal of imaging informatics in medicine2026-10-15

Performance Analysis of Laplacian Re-Decomposition-Based PET-MRI Fusion for Quantitative Imaging Biomarkers in Alzheimer's Disease Classification.

Moslehi Masoud M, Sharma Rahul R, Khorasani Amir A, Alzheimer’s Disease NeuroimagingInitiative

Alzheimer's disease (AD) and mild cognitive impairment (MCI) represent critical stages along the continuum of cognitive decline. This study investigates the Laplacian Re-decomposition (LRD) method for fusing positron emission tomography (PET) and magnetic resonance imaging (MRI) to develop a quantitative imaging biomarker for the classification of AD. Data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database were used in this study. T1, T2, T2-FLAIR, and T2*-weighted MRI sequences, together with [18F]FDG-PET images, were preprocessed and fused using the LRD algorithm. Hippocampal and frontal lobe WM segmentation, performed via U-Net, enabled relative signal contrast (RSC) calculation as a quantitative biomarker for each modality and fused image. Fusion and segmentation performance were assessed using standard metrics. RSC statistically compared between diagnostic groups after adjustment for demographic confounds, and evaluated for classification performance using ROC/AUC analysis. The mean Dice coefficient achieved by the trained U-Net for hippocampus and frontal lobe WM segmentation were 0.93 and 0.95, respectively. ROC analysis revealed that the RSC extracted from T1-weighted images fused with PET outperformed other modalities for AD vs. Cognitively normal (CN) classification (AUC = 0.88, accuracy = 0.90). Also, T2-weighted images fused with PET, using RSC as a quantitative biomarker, achieved the best classification performance for AD vs. MCI (AUC = 0.81, accuracy = 0.81) and MCI vs. CN (AUC = 0.84, accuracy = 0.88) classification. Our findings indicate that RSC extracted from LRD-fused images achieves competitive classification performance, supporting its potential as a quantitative biomarker for AD.

PMID 42875694
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about SH-U-454